From GlobeNewswire:

Singular Genomics Systems, Inc. announced preliminary Q4 2023 revenue of approximately $1.0 million and the shipment of eight G4 instruments during that time. This represents a 31% growth compared to the same period in 2022. The company reported notable momentum in 2023, with the launch of high-impact consumable kits and other initiatives. The preliminary results are subject to further review and audit by external auditors. Future financial results will be released in March 2024, and more details about the company’s technology and mission can be found at singulargenomics.com.



Read more: Singular Genomics Reports Instrument Shipments and